GlassScriptPhysician profile
Peter J Litwin
NPI 1154452712
$1,167.68
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $139 · 2020: $166 · 2021: $208 · 2022: $656.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $249.19 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $238.28 | 2020-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $159.68 | 2021-2022 | |
| Jazz Pharmaceuticals INC. | $102.97 | 2019 | |
| Indivior INC. | $100.95 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $59.92 | 2021-2022 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $58.00 | 2019-2022 | |
| Alkermes, INC. | $43.58 | 2022 | |
| Sunovion Pharmaceuticals INC. | $34.94 | 2019-2020 | |
| Bausch Health US, LLC | $32.10 | 2020-2021 | |
| Allergan, INC. | $30.52 | 2020 | |
| Avanir Pharmaceuticals, INC. | $16.97 | 2021 | |
| Vanda Pharmaceuticals INC. | $14.16 | 2022 | |
| Neurocrine Biosciences, INC. | $13.48 | 2022 | |
| Lundbeck LLC | $12.94 | 2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Litwin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.